Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

Summary

This is a Phase 1b, multicenter, open-label, dose-escalation study designed to estimate the maximum tolerated dose (MTD) and determine the recommended Phase 2 dose (RP2D) of ADXS31-164. Once the RP2D has been selected, up to 4 expansion cohorts will be evaluated.

Timeline

Start

2015-09

Primary completion

2017-04

Completion

2018-09

Drugs

Indications

No indication recorded.